Evidence map›Paper›PMID 40741889›Full record

ReviewFEBS letters2025

Goodbye flat lymphoma biology.

Carla Faria, Cèlia Dobaño-López, Patricia Pérez-Galán, Christine Bezombes

Abstract readReview
In one paragraph

Review in FEBS letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carla FariaOncology Department, UNIL-CHUV, Bernhard Gentner Laboratory, Agora Research Center, Lausanne, Switzerland.
Cèlia Dobaño-LópezMolecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID https://orcid.org/0000-0001-9248-9883
Patricia Pérez-GalánFundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.ORCID https://orcid.org/0000-0003-3895-5024
Christine BezombesINSERM, CRCT, Univ Toulouse, France.

Funding

CNRSEuropean Regional Development Fund (ERDF) 16006947/MP0008755Institut Claudius Regaud R20027BBInstitut National de la Santé et de la Recherche MédicaleInterreg POCTEFA program IMLINFO EFA281/16Interreg POCTEFA program THERAVLINFO EFA 123/1Laboratoire d'Excellence Toulouse Cancer (TOUCAN-2) G20000BB'la Caixa' Foundation HR22-00395Ministerio de Economía y Competitividad PID2021-124894OB-I00Ministerio de Economía y Competitividad PRE2018-083797Région Occitanie Midi Pyrénées 16003518Université de Toulouse
6 · The paper itself

Abstract

B-cell lymphomas grow in aggregates, closely interacting with specific physical elements and cellular environments. While 2D culture systems have long been the standard in the field, current methodologies aim to better replicate lymphoma biology and its microenvironment in 3D. Significant progress has been made since the first 3D lymphoma cell line culture was developed in 2012. Subsequent advances in both cell line and patient-derived systems have incorporated key physical and cellular microenvironmental components. This Review compiles the relevant 3D non-Hodgkin lymphoma models available, outlining their main features, strengths, and limitations. Additionally, we highlight the critical gaps that must be addressed to develop robust, multiplexed, patient-derived B-cell lymphoma systems, which can serve as reliable avatars alongside clinical trials and contribute to the principles of the 3Rs in animal research. Impact statement In the last few years new B-cell lymphoma 3D models have emerged, with a special emphasis on patient-derived models. These systems are fundamental tools for precision medicine. This review provides translational researchers and clinician scientists with an excellent overview of these novel tools with their strong and weak points.

Indexed as

Lymphoma, B-CellAnimalsCell Line, TumorHumansTumor Microenvironmentdiffuse large B‐cell lymphomafollicular lymphomalymphoma‐on‐chipmantle cell lymphomanon‐Hodgkin lymphomapatient‐derived lymphoma modelspreclinical 3D models

Identifiers

PMID40741889
PMCPMC12558674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.